ProMetic's PBI-1402 Abstract Available Through American Society of
Hematology's Web Site
MONTREAL, QUEBEC -- (MARKET WIRE) -- 11/13/07 -- ProMetic Life
Sciences Inc. (TSX: PLI) ("ProMetic") announced today that ProMetic's
abstract on its PBI-1402 Phase II clinical trial in patients with
chemotherapy-induced anemia ("CIA") is now available on the American
Society of Hematology's ("ASH") Web site under the heading "Annual
Meeting Abstracts" http://www.hematology.org/meetings/2007/index.cfm.
More substantive information will be reported in conjunction with a
poster to be presented at ASH's annual meeting on December 9, 2007.
About PBI-1402
PBI-1402 is an orally active compound being developed to treat
different types of anemia, such as CIA. ProMetic has recently
expanded its clinical program for PBI-1402 for treatment of patients
with cancer-related anemia, such as myelodysplastic syndrome, a
condition often referred to as "pre-leukemia". Clinical trials in
patients with anemia associated to chronic kidney diseases are also
scheduled to commence shortly.
About chemotherapy-induced anemia ("CIA")
Anemia is one of the most serious side effects caused by
chemotherapy. Anemia is a condition in which red blood cells and
hemoglobin are below normal levels. CIA is associated with a reduced
quality of life and possible compromised treatment outcomes. Of the
estimated 1.3 million new patients that undergo chemotherapy annually
in the U.S., it is believed that approximately two third of these
patients will develop CIA. Certain types of chemotherapy regimens are
associated with more frequent and severe anemia often leading to the
patients requiring blood transfusions. The treatment with rhEPO is
active in only 50-60 percent of CIA patients. Typical doses of rhEPO
required to treat CIA patients are two- to three-fold higher than
those used to treat anemia in dialysis patients.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and
marketing of a variety of commercial applications derived from its
proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of
pathogens. ProMetic is also active in therapeutic drug development
with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of hematology and cancer.
Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montreal (Canada), ProMetic has R&D facilities in
the U.K., the U.S. and Canada, manufacturing facilities in the U.K.
and business development activities in the US, Europe, Asia and in
the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about
ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events or
results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, ProMetic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and general
changes in economic conditions. You will find a more detailed
assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of
ProMetic's Annual Information Form for the year ended December 31,
2006, under the heading "Risk Factors". As a result, we cannot
guarantee that any forward-looking statement will materialize. We
assume no obligation to update any forward-looking statement even if
new information becomes available, as a result of future events or
for any other reason.
Contacts:
ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
+1-514-341-2115
p.laurin@prometic.com
ProMetic Life Sciences Inc.
Anne Leduc
Manager, Communications
+1-514-341-2115 ext. 2234
a.leduc@prometic.com
Echoes Financial Network Inc.
Dominic Sicotte
+1-514-842-9551
dsicotte@echoesfinancial.com
Lippert / Heilshorn & Associates
Bruce Voss
+1-310-691-7100
BVoss@lhai.com
Lippert / Heilshorn & Associates
Kim Golodetz
+1-212-838-3777
KGolodetz@lhai.com
